Amarin Corp Plcuk (AMRN) Total Current Liabilities (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Total Current Liabilities of $164.2 million for Q2 2026, down 11.7% year-over-year from $185.9 million in Q2 2025, and down 8.6% quarter-over-quarter from $179.6 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Total Current Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Total Current Liabilities for 17 consecutive years, with $164.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Current Liabilities fell 11.7% year-over-year to $164.2 million; the TTM figure through Jun 2026 stood at $164.2 million (down 11.7% YoY), while the FY2025 annual figure was $194.5 million, up 8.06% from the prior year.
- Total Current Liabilities declined to $164.2 million in Q2 2026 per AMRN's latest filing, from $179.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $361.6 million in Q2 2022 and bottomed at $162.4 million in Q1 2025.
- Historically, Total Current Liabilities has averaged $230.9 million across 5 years, with a median of $227.5 million in 2024.
- Annual changes were most pronounced in 2024 — Total Current Liabilities sank 30.6% — and 2026, when it gained 10.61%.
- Amarin Corp Plc\Uk's Total Current Liabilities stood at $259.5 million in 2022, then dropped by 0.08% to $259.3 million in 2023, then tumbled by 30.6% to $179.9 million in 2024, then rose by 8.06% to $194.5 million in 2025, then decreased by 15.56% to $164.2 million in 2026.
- Business Quant data shows AMRN's Total Current Liabilities at $164.2 million in Q2 2026, $179.6 million in Q1 2026, and $194.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 164.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 164.20 Mn |
| Mar 31, 2026 | 179.64 Mn |
| Dec 31, 2025 | 194.46 Mn |
| Sep 30, 2025 | 182.23 Mn |
| Jun 30, 2025 | 185.95 Mn |
| Mar 31, 2025 | 162.41 Mn |
| Dec 31, 2024 | 179.95 Mn |
| Sep 30, 2024 | 201.55 Mn |
| Jun 30, 2024 | 230.54 Mn |
| Mar 31, 2024 | 224.38 Mn |
| Dec 31, 2023 | 259.28 Mn |
| Sep 30, 2023 | 266.69 Mn |
| Jun 30, 2023 | 270.93 Mn |
| Mar 31, 2023 | 244.24 Mn |
| Dec 31, 2022 | 259.48 Mn |
| Sep 30, 2022 | 287.36 Mn |
| Jun 30, 2022 | 361.57 Mn |
| Mar 31, 2022 | 300.57 Mn |
| Dec 31, 2021 | 370.68 Mn |
| Sep 30, 2021 | 364.75 Mn |